Brandon E. Kremer

2.3k total citations
37 papers, 1.2k citations indexed

About

Brandon E. Kremer is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Brandon E. Kremer has authored 37 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 19 papers in Hematology and 9 papers in Oncology. Recurrent topics in Brandon E. Kremer's work include Multiple Myeloma Research and Treatments (18 papers), Protein Degradation and Inhibitors (17 papers) and Peptidase Inhibition and Analysis (5 papers). Brandon E. Kremer is often cited by papers focused on Multiple Myeloma Research and Treatments (18 papers), Protein Degradation and Inhibitors (17 papers) and Peptidase Inhibition and Analysis (5 papers). Brandon E. Kremer collaborates with scholars based in United States, United Kingdom and Canada. Brandon E. Kremer's co-authors include Ian G. Macara, Laura Adang, Timothy Haystead, Sanjay Sinha, Gary K. Owens, Frédéric Dandré, Da‐Zhi Wang, Mark H. Hoofnagle, Brian R. Wamhoff and Eric N. Olson and has published in prestigious journals such as Cell, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Brandon E. Kremer

33 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brandon E. Kremer United States	14	833	231	192	131	120	37	1.2k
Bartolomé Seguí‐Real United States	13	738 0.9×	307 1.3×	138 0.7×	121 0.9×	97 0.8×	15	1.3k
Yoko K. Takada United States	21	543 0.7×	148 0.6×	209 1.1×	60 0.5×	80 0.7×	35	1.0k
Rachel L. Dusek United States	13	783 0.9×	325 1.4×	287 1.5×	67 0.5×	42 0.3×	27	1.2k
Christine B. Kern United States	23	1.0k 1.2×	271 1.2×	148 0.8×	183 1.4×	65 0.5×	39	1.6k
Dalia Pinchasi Israel	8	648 0.8×	365 1.6×	136 0.7×	50 0.4×	63 0.5×	8	927
Daizo Murakami Japan	11	406 0.5×	281 1.2×	241 1.3×	144 1.1×	38 0.3×	42	1.0k
Ilka Warshawsky United States	19	561 0.7×	177 0.8×	141 0.7×	96 0.7×	291 2.4×	33	1.2k
Laura Oliva Italy	12	849 1.0×	220 1.0×	141 0.7×	91 0.7×	266 2.2×	19	1.3k
Xiaojie Xian Sweden	10	687 0.8×	236 1.0×	176 0.9×	91 0.7×	22 0.2×	12	1.0k
Kevin M. Pawlik United States	15	1.2k 1.4×	105 0.5×	120 0.6×	93 0.7×	262 2.2×	21	1.7k

Countries citing papers authored by Brandon E. Kremer

Since Specialization

Citations

This map shows the geographic impact of Brandon E. Kremer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brandon E. Kremer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brandon E. Kremer more than expected).

Fields of papers citing papers by Brandon E. Kremer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brandon E. Kremer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brandon E. Kremer. The network helps show where Brandon E. Kremer may publish in the future.

Co-authorship network of co-authors of Brandon E. Kremer

This figure shows the co-authorship network connecting the top 25 collaborators of Brandon E. Kremer. A scholar is included among the top collaborators of Brandon E. Kremer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brandon E. Kremer. Brandon E. Kremer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fulci, Giulia, et al.. (2025). Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Comprehensive Exposure-Response Analysis of the DREAMM-8 Study. Targeted Oncology. 20(5). 833–845.

Lonial, Sagar, Ho‐Young Yhim, Vanesa Caruso, et al.. (2025). Design of the phase 3 DREAMM-10 study: Belantamab mafodotin plus lenalidomide and dexamethasone (BRd) vs daratumumab plus lenalidomide and dexamethasone (DRd) in transplant-ineligible, newly diagnosed multiple myeloma (TI-NDMM).. Journal of Clinical Oncology. 43(16_suppl). 1 indexed citations

Trudel, Suzanne, Meral Beksaç, Luděk Pour, et al.. (2024). Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 42(17_suppl). LBA105–LBA105. 2 indexed citations

Iida, Shinsuke, et al.. (2023). Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11. International Journal of Hematology. 118(5). 596–608. 3 indexed citations

Kalaitzaki, Eleftheria, Shuai Yuan, Alessandra Tosolini, et al.. (2023). Association of Minimal Residual Disease Negativity Rates With Progression Free Survival in Frontline Therapy Trials for Newly Diagnosed Multiple Myeloma: A Meta-analysis. Clinical Lymphoma Myeloma & Leukemia. 23(5). e213–e221. 9 indexed citations

Quach, Hang, Giulia Fulci, John D. Clements, et al.. (2023). P983: DREAMM-20: A STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF BELANTAMAB FOR THE TREATMENT OF MULTIPLE MYELOMA WHEN USED AS MONOTHERAPY AND IN COMBINATION TREATMENTS. HemaSphere. 7(S3). e366180e–e366180e.

Lonial, Sagar, Sebastian Grosicki, Marek Hus, et al.. (2022). Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study.. Journal of Clinical Oncology. 40(16_suppl). 8019–8019. 17 indexed citations

Medaglia, Alice Annalisa, Ajay K. Nooka, Nizar J. Bahlis, et al.. (2020). Dreamm-4: evaluating safety and clinical activity of belantamab mafodotin (belamaf) in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (rrmm). SHILAP Revista de lepidopterología. 1 indexed citations

Cousin, Sophie, Jean‐Yves Blay, Irene García, et al.. (2020). BET inhibitor molibresib for the treatment of advanced solid tumors: Final results from an open-label phase I/II study.. Journal of Clinical Oncology. 38(15_suppl). 3618–3618. 5 indexed citations

10.

Patel, Aarti, et al.. (2020). An Adaptive Physiologically Based Pharmacokinetic–Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers. The Journal of Clinical Pharmacology. 61(1). 125–137. 8 indexed citations

11.

Trudel, Suzanne, Randy Davis, Nicole Lewis, et al.. (2020). DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 136(Supplement 1). 4–4. 23 indexed citations

12.

Kremer, Brandon E., Donald E. Tsai, Fotini Debonera, Patti Cohen, & Stephen J. Schuster. (2017). Spontaneous remission of acute myeloid leukemia after discontinuation of lenalidomide. Leukemia & lymphoma. 59(3). 743–745. 2 indexed citations

13.

Melo, Guilherme Dias de, et al.. (2015). Blood–brain barrier disruption during spontaneous canine visceral leishmaniasis. Parasite Immunology. 37(12). 635–645. 8 indexed citations

14.

Kremer, Brandon E., Ran Reshef, Jamal Misleh, et al.. (2011). Post-transplant lymphoproliferative disorder after lung transplantation: A review of 35 cases. The Journal of Heart and Lung Transplantation. 31(3). 296–304. 35 indexed citations

15.

Kremer, Brandon E., Laura Adang, & Ian G. Macara. (2007). Septins Regulate Actin Organization and Cell-Cycle Arrest through Nuclear Accumulation of NCK Mediated by SOCS7. Cell. 130(5). 837–850. 181 indexed citations

16.

Kremer, Brandon E., Timothy Haystead, & Ian G. Macara. (2005). Mammalian Septins Regulate Microtubule Stability through Interaction with the Microtubule-binding Protein MAP4. Molecular Biology of the Cell. 16(10). 4648–4659. 160 indexed citations

17.

Sheffield, Peter, Carey J. Oliver, Brandon E. Kremer, et al.. (2003). Borg/Septin Interactions and the Assembly of Mammalian Septin Heterodimers, Trimers, and Filaments. Journal of Biological Chemistry. 278(5). 3483–3488. 139 indexed citations

18.

Hof, J.R., Brandon E. Kremer, & J. J. Manni. (2000). Mould constituents in the middle ear, a hearing-aid complication. The Journal of Laryngology & Otology. 114(1). 50–52. 20 indexed citations

19.

Henne‐Bruns, Doris, Brandon E. Kremer, Frank Thonke, H. Grimm, & N. Soehendra. (1993). “Endoscopy Friendly” Resection Technique of Choledochal Cysts. Endoscopy. 25(2). 176–178. 7 indexed citations

20.

Weber, Bernhard H. F., et al.. (1988). Modulation by palmitoyl-carnitine of calcium activated, phospholipid-dependent protein kinase activity and inhibition of melanoma cell growth. British Journal of Dermatology. 119(2). 171–178. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact